File Download

There are no files associated with this item.

Supplementary

Conference Paper: The influence of income and education on drug purchasing decisions in Hong Kong Chinese cancer patients

TitleThe influence of income and education on drug purchasing decisions in Hong Kong Chinese cancer patients
Authors
Issue Date2007
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.asco.org/ASCOv2/Meetings/ASCO+Annual+Meeting
Citation
A S C O Annual Meeting Proceedings, 2007, v. 43, p. 713 How to Cite?
AbstractBackground: Inflation of anticancer drug prices is a growing problem worldwide. This problem is especially challenging in Asia, where rising healthcare expectations clash with low incomes and weak insurance. To clarify the factors influencing drug purchasing decisions in this context, we conducted a survey of Hong Kong oncology patients. Methods: A questionnaire was designed to assess the effect of cost on purchasing decisions relating to drug variables such as (1) efficacy, (2) tolerability, (3) convenience, (4) safety, (5) novelty and (6) reliability. Validation of the original 33-part survey resulted in a final set of 21 questions that was administered to 51 oncology patients. These respondents were characterised in terms of age, household income, insurance, educational level, family circumstances, occupation, ethnicity, religious beliefs, prognosis, and co-morbidity. Results: Most respondents were Hong Kong (68.8%), mainland Chinese (18.8%) or Caucasian (10.4%). There was a strong correlation between household income and education. Patients from middle-income (US$7,000–14,000 per month) households were most influenced in their decisions by costs and insurance rebates, whereas those from low-income households (less than US$3,000 per month) were keenest to purchase expensive medications, whether Western or traditional Chinese remedies. Demand for drug safety was cost-inelastic across all income groups, independent of gains in efficacy. Even when free treatment was offered, therapeutic uncertainties (e.g., early-phase drugs or randomization) proved unpopular with all income groups. Only the most affluent and well-educated patients valued overall survival above disease-free survival in making decisions, suggesting that less educated cohorts did not understand these concepts. Conclusion: These data suggest that low-income cancer patients and their families may have unrealistic expectations of high-priced medications, based either on misunderstanding or cultural pressures. Greater educational efforts targeting this large population sector may be needed to avoid worsening dissatisfaction and social unrest in the future.
Persistent Identifierhttp://hdl.handle.net/10722/77495

 

DC FieldValueLanguage
dc.contributor.authorChan, TWMen_HK
dc.contributor.authorChan, Sen_HK
dc.contributor.authorPoon, Yen_HK
dc.contributor.authorFok, Jen_HK
dc.contributor.authorEpstein, JAen_HK
dc.contributor.authorMak, Jen_HK
dc.contributor.authorEpstein, Ren_HK
dc.date.accessioned2010-09-06T07:32:31Z-
dc.date.available2010-09-06T07:32:31Z-
dc.date.issued2007en_HK
dc.identifier.citationA S C O Annual Meeting Proceedings, 2007, v. 43, p. 713en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77495-
dc.description.abstractBackground: Inflation of anticancer drug prices is a growing problem worldwide. This problem is especially challenging in Asia, where rising healthcare expectations clash with low incomes and weak insurance. To clarify the factors influencing drug purchasing decisions in this context, we conducted a survey of Hong Kong oncology patients. Methods: A questionnaire was designed to assess the effect of cost on purchasing decisions relating to drug variables such as (1) efficacy, (2) tolerability, (3) convenience, (4) safety, (5) novelty and (6) reliability. Validation of the original 33-part survey resulted in a final set of 21 questions that was administered to 51 oncology patients. These respondents were characterised in terms of age, household income, insurance, educational level, family circumstances, occupation, ethnicity, religious beliefs, prognosis, and co-morbidity. Results: Most respondents were Hong Kong (68.8%), mainland Chinese (18.8%) or Caucasian (10.4%). There was a strong correlation between household income and education. Patients from middle-income (US$7,000–14,000 per month) households were most influenced in their decisions by costs and insurance rebates, whereas those from low-income households (less than US$3,000 per month) were keenest to purchase expensive medications, whether Western or traditional Chinese remedies. Demand for drug safety was cost-inelastic across all income groups, independent of gains in efficacy. Even when free treatment was offered, therapeutic uncertainties (e.g., early-phase drugs or randomization) proved unpopular with all income groups. Only the most affluent and well-educated patients valued overall survival above disease-free survival in making decisions, suggesting that less educated cohorts did not understand these concepts. Conclusion: These data suggest that low-income cancer patients and their families may have unrealistic expectations of high-priced medications, based either on misunderstanding or cultural pressures. Greater educational efforts targeting this large population sector may be needed to avoid worsening dissatisfaction and social unrest in the future.-
dc.languageengen_HK
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.asco.org/ASCOv2/Meetings/ASCO+Annual+Meetingen_HK
dc.relation.ispartofA S C O Annual Meeting Proceedingsen_HK
dc.titleThe influence of income and education on drug purchasing decisions in Hong Kong Chinese cancer patientsen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChan, TWM: tracychan6@i-cable.comen_HK
dc.identifier.emailEpstein, R: repstein@hku.hken_HK
dc.identifier.authorityEpstein, R=rp00501en_HK
dc.identifier.hkuros131724en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats